RARE (Ultragenyx Pharmaceutical) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RARE Ultragenyx Pharmaceutical Inc RARE
69 GF Score
Price $25.91
GF Value $45.41
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical  (NAS:RARE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Related Terms


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.79 3.87 3.42 2.08

Ultragenyx Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.59 2.08 1.94 3.19

RARE vs ATAI, QURE, KOD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


RARE
69GF Score
Ultragenyx Pharmaceutical Inc RARE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.856/333.9520*333.9520
=-2.856

Current CPI (Jun. 2026) = 333.9520.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201609 11.382 241.428 15.744
201612 11.493 241.432 15.897
201703 11.555 243.801 15.828
201706 10.122 244.955 13.800
201709 8.604 246.819 11.641
201712 8.682 246.524 11.761
201803 14.571 249.554 19.499
201806 14.047 251.989 18.616
201809 13.112 252.439 17.346
201812 11.972 251.233 15.914
201903 15.474 254.202 20.329
201906 14.216 256.143 18.534
201909 12.593 256.759 16.379
201912 11.303 256.974 14.689
202003 10.240 258.115 13.249
202006 11.514 257.797 14.915
202009 10.954 260.280 14.055
202012 17.276 260.474 22.149
202103 15.638 264.877 19.716
202106 14.346 271.696 17.633
202109 13.738 274.310 16.725
202112 13.304 278.802 15.936
202203 11.411 287.504 13.255
202206 9.685 296.311 10.915
202209 6.690 296.808 7.527
202212 5.021 296.797 5.650
202303 3.120 301.836 3.452
202306 1.805 305.109 1.976
202309 0.439 307.789 0.476
202312 3.346 306.746 3.643
202403 1.688 312.332 1.805
202406 4.693 314.175 4.988
202409 3.757 315.301 3.979
202412 2.757 315.605 2.917
202503 1.536 319.799 1.604
202506 1.570 322.561 1.625
202509 0.095 324.800 0.098
202512 -0.829 324.054 -0.854
202603 -2.400 330.213 -2.427
202606 -2.856 333.952 -2.856

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $25.91 is trading 43% below its estimated GF Value™ of $45.41. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for RARE:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $45.41 vs. price of $25.91 (43% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
69GF Score

Get the complete analysis for RARE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.91
Price
$45.41
GF Value